RCE.ASX: Placement & SPP to raise $8 million

Placement & SPP to raise $8 million

Stock	Recce Pharmaceuticals Ltd (RCE.ASX)
Release Time	26 Jun 2026, 10:03 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Recce Pharmaceuticals Raises A$8 Million via Placement and SPP

Key Points

Recce Pharmaceuticals raises A$4 million via institutional placement
Share Purchase Plan to raise an additional A$4 million
Funds to support commercial licensing, clinical trials, and R&D activities
Offer price at A$0.40 per share, a discount to recent market prices

Full Summary

Recce Pharmaceuticals Ltd (ASX:RCE) has successfully raised A$4 million via an institutional placement at A$0.40 per share. The Company is also launching a Share Purchase Plan (SPP) to raise an additional A$4 million on the same terms. The funds will be used to strengthen the balance sheet for commercial licensing, fund clinical trials, support Investigational New Drug activities, and provide general working capital. The placement was well-supported by new and existing institutional, sophisticated, and professional investors. Eligible shareholders will have the opportunity to participate in the SPP, which will offer attaching options and piggyback options. The Company expects to have approximately A$29.5 million in liquidity post the offer.

Guidance

Recce Pharmaceuticals expects to have approximately A$29.5 million in liquidity post the offer.

Outlook

Recce Pharmaceuticals looks forward to providing updates on progress towards commercialization of R327G and other key milestones.